

SCIENTIFIC REPORTS



OPEN

High therapeutic efficacy of Cathelicidin-WA against postweaning diarrhea via inhibiting inflammation and enhancing epithelial barrier in the intestine

Received: 24 February 2016

Accepted: 20 April 2016

Published: 16 May 2016

Hongbo Yi, Lin Zhang, Zhenshun Gan, Haitao Xiong, Caihua Yu, Huahua Du & Yizhen Wang

Diarrhea is a leading cause of death among young mammals, especially during weaning. Here, we investigated the effects of Cathelicidin-WA (CWA) on diarrhea, intestinal morphology, inflammatory responses, epithelial barrier and microbiota in the intestine of young mammals during weaning. Piglets with clinical diarrhea were selected and treated with saline (control), CWA or enrofloxacin (Enro) for 4 days. Both CWA and Enro effectively attenuated diarrhea. Compared with the control, CWA decreased IL-6, IL-8 and IL-22 levels and reduced neutrophil infiltration into the jejunum. CWA inhibited inflammation by down-regulating the TLR4-, MyD88- and NF- κ B-dependent pathways. Additionally, CWA improved intestinal morphology by increasing villus and microvillus heights and enhancing intestinal barrier function by increasing tight junction (TJ) protein expression and augmenting wound-healing ability in intestinal epithelial cells. CWA also improved microbiota composition and increased short-chain fatty acid (SCFA) levels in feces. By contrast, Enro not only disrupted the intestinal barrier but also negatively affected microbiota composition and SCFA levels in the intestine. In conclusion, CWA effectively attenuated inflammation, enhanced intestinal barrier function, and improved microbiota composition in the intestines of weaned piglets. These results suggest that CWA could be an effective and safe therapy for diarrhea or other intestinal diseases in young mammals.

Diarrhea is a leading cause of death among children under 5 years of age, and causes death in more than one in ten children (approximately 800,000) per year, mainly in developing countries (WHO, 2015). Diarrhea typically occurs during the weaning period, which is a critical and stressful stage for young mammals^{1,2}. Weaning causes reductions in body weight gain, decreases in nutrient absorption, disruptions to immune homeostasis and damage to barrier function³⁻⁶, resulting in susceptibility to pathogen infection and diarrhea⁷. Antibiotics have been effectively used to treat diarrhea in children and other animal neonates after weaning in past decades. Unfortunately, the widespread use of antibiotics has increased bacterial resistance, leading to delayed administration of effective therapy as well as morbidity and mortality in both humans and animals^{8,9}. As reported, antimicrobial-resistant infections cause more than 700,000 deaths each year globally: at least 23,000 in the USA and 175,000 in the EU^{10,11}. Furthermore, the development of new antibiotics has slowed down, and few antibiotics have been approved by the FDA in recent years¹⁰. Moreover, recent studies have reported that therapeutic or sub-therapeutic antibiotic treatments in early life have long-term consequences on intestinal microbiota composition and metabolic homeostasis in the host^{12,13}. All this makes it clear that it is urgent to search effective and safe antimicrobial agents.

Antimicrobial peptides (AMPs) are short cationic molecules that serve as a host defense against microbial infection^{14,15}. It is not easy for bacteria to develop resistance to AMPs because they work through a membrane-disrupting mechanism; therefore, they are considered a promising alternative to traditional antibiotics¹⁶. Cathelicidin peptides, such as human LL-37 and mouse CRAMP, exhibit antibacterial, antifungal and

Institute of Feed Science, College of Animal Science, Zhejiang University, 866Yuhangtang Road, Hangzhou, Zhejiang 310058, China. Correspondence and requests for materials should be addressed to H.D. (email: huahuadu@zju.edu.cn) or Y.W. (email: yzwang321@zju.edu.cn)

antiviral functions¹⁷. These peptides not only kill microbes directly but also modulate the immune system of the host^{9,15}. LL-37 was shown to enhance the defenses of rats against pathogen infection, and CRAMP was found to ameliorate colonic colitis in dextran sulfate sodium (DSS)-induced mice¹⁸. Cathelicidin-WA (CWA), an AMP derived from the endemic genera *Bungarus fasciatus*, is considered a potent alternative to antibiotics^{19,20}. Previous studies have shown that CWA had strong antimicrobial activities against ciprofloxacin-resistant pathogens and enteric pathogens isolated from the feces of piglets with diarrhea^{21,22}. Our studies have revealed that CWA is highly unstable in gastrointestinal tract, but remains substantially intact in serum; the *in vivo* imaging results showed that intraperitoneal injection with CWA could be absorbed into the systemic circulation and availability to the intestine. Furthermore, CWA showed immunoregulatory capabilities *in vivo* and *in vitro*¹⁷.

The objective of this study was to investigate whether the CWA could be an effective therapy for diarrhea during weaning and to explore the immunoregulatory and epithelial barrier protective properties of CWA in the intestine of weaned piglets.

Materials and Methods

Peptide synthesis. CWA was synthesized by GL Biochem (Shanghai, China) as previously described²³. Peptides were purified at greater than 95% purity via semi-preparative HPLC and characterized by analytical HPLC (Agilent 121 Technologies, CA, USA). The molecular weight of CWA was confirmed using a Thermo Finnigan LCQ ion trap mass spectrometer (Thermo Finnigan, CA, USA). CWA was prepared in saline before injection.

Animals and sample collection. All experiments were approved by the Animal Care Committee of Zhejiang University and were conducted in accordance with the Guidelines for the Care and Use of Agricultural Animals for Research and Teaching at Zhejiang University. A total of 108 piglets with clinical diarrhea were selected from 1260 piglets (Duroc × Landrace × Yorkshire) at 3 d after weaning (25 ± 2 d). The piglets were randomly assigned to 1 of 3 treatments based on body weight, gender and diarrheal index. In total, there were 6 pens for each treatment, with 6 piglets per pen. The piglets were treated by intraperitoneal injection with normal saline (control), 0.6 mg/kg CWA (the dosage was based on results from LPS-induced mice and pre-experiment in diarrheal piglets), or 2.5 mg/kg enrofloxacin (Enro) once a day for 4 d. All piglets were provided with access to the diet (NRC1998) and water *ad libitum*. The diarrheal index was scored according to a fecal consistency scoring system (0, normal; 1, soft feces; 2, mild diarrhea; and 3, severe diarrhea) as described before²⁴. A fecal score of 2 or 3 was considered clinical diarrhea. Fresh feces from each pen was collected and stored immediately at -20 °C. One piglet from each pen was randomly euthanized (n = 6 per treatment). Blood samples were collected from the anterior vena cava into coagulation accelerator tubes. Serum was obtained after centrifugation at 3000 × g for 10 min at 4 °C. Samples of the middle duodenum, middle jejunum, distal ileum and middle colon were collected for analysis.

Enzyme-linked immunosorbent assay (ELISA). The levels of IL-6, IL-8 and IL-22 in serum and the jejunum were determined using ELISA kits (Raybiotech, GA, USA). In addition, the level of D-Lactate (D-Lac) in serum was detected using an ELISA kit (R&D, USA). Samples were measured according to the manufacturers' instructions.

Analysis of intestinal morphology. Intestinal tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections of 5-µm thickness were stained with hematoxylin and eosin (H&E). Images were acquired using a DM3000 microscope (Leica, Wetzlar, Germany). Villous height and crypt depth were measured using Image-Pro software (MediaCybernetics, MD, USA) as previously described²⁵. Histopathologic damage scores were determined under blinded conditions using a histologic injury scale (0, normal mucosal villi; 1, subepithelial Gruenha-gen's space; 2, extension of subepithelial space with moderate lifting of epithelial layer from the lamina propria; 3, massive epithelial lifting down the sides of villi; 4, denuded villi with lamina propria and dilated capillaries exposed; and 5, digestion and disintegration of lamina propria) as previously described²³.

Scanning electron microscopy (SEM). Jejunum tissue was fixed with 2.5% glutaraldehyde overnight and then with 1% OsO₄ for 1 h. The jejunum specimens were then dehydrated in a graded series of ethanol (30%, 50%, 70%, 80%, 90%, 95% and 100%) for 20 min at each step and then transferred into a mixture of alcohol and iso-amyl acetate (v:v = 1:1) for 30 min and iso-amyl acetate for 1 h. The specimens were then dehydrated in a Hitachi Model HCP-2 critical point dryer with liquid CO₂. The dehydrated specimens were coated with gold-palladium and visualized using a Philips Model SU8010 FASEM (HITACHI, Japan).

Transmission electron microscopy (TEM). Microvilli and epithelial cell junctions were observed by TEM. Jejunum tissue was fixed, dehydrated, and transferred into pure acetone for 20 min. The specimens were placed in a mixture of pure acetone and Spurr resin mixture (1:1 for 1 h and 1:3 for 3 h) and then transferred into Spurr resin mixture overnight. The tissue sections were placed in capsules containing embedding medium and heated at 70 °C for 9 h. The sections were then stained with uranyl acetate and alkaline lead citrate for 15 min and visualized via TEM (Model H-7650, HITACHI, Japan).

Immunohistochemistry. Briefly, sections of jejunum were deparaffinized and rehydrated. The sections were submitted to antigen retrieval using EDTA buffer (pH = 9.0) and a microwave and then incubated in 3% hydrogen dioxide in the dark for 20 min. Following this, the sections were incubated with a primary antibody (1:200 dilution) against myeloperoxidase (MPO; Google Biotechnology Inc., Wuhan, China) to detect neutrophil infiltration. Sections were then incubated with a secondary antibody (1:200 dilution) and treated with DAB substrate. Nuclei were stained with Harris hematoxylin. Images were obtained using a DM3000 microscope.

Gene	Sequence (5'–3')	Size(bp)	Accession number
TLR4	Forward: GCCATCGCTGTAACATCATC Reverse: CTCATACTCAAAGATACACCATCGG	108	NM_001113039.1
MyD88	Forward: TGGTAGTGGTTGTCTCTGATGA Reverse: TGGAGAGAGGCTGAGTGCAA	80	NM_001099923.1
Mucin-1	Forward: ACACCCATGGGCGCTATGT Reverse: GCCTGCAGAAACCTGCTCAT	68	NM_001204296.1
Mucin-2	Forward: CTGCTCCGGTCTCTGTGGGA Reverse: CCCGCTGGCTGGTGCGATAC	100	XM_007465997.1
pBD2	Forward: CCAGAGGTCCGACCACTACA Reverse: GGTCCCTTCAATCCTGTTGAA	88	AY506573.1
18S	Forward: CCCACGGAATCGAGAAAGAG Reverse: TTGACGGAAGGGCACCA	122	AY265350.1
GAPDH	Forward: ACTCACTCTCCACTTTTGATGCT Reverse: TGTTGCTGTAGCCAAATCA	100	NM_001206359

Table 1. Primers for real-time PCR in this study.

Real-time PCR. Total RNA was extracted using TRIzol reagent (Invitrogen, USA). RNA quantity and quality were determined using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, MA, USA). cDNA was obtained using 2 µg RNA. Real-time PCR was performed using a StepOne Plus™ system (Applied Biosystems, CA, USA). The primers used for real-time PCR are listed in Table 1. Each reaction included 5 µL FastStart Universal SYBR Green Master Mix (Roche, Switzerland), 0.5 µL forward primer (10 µM), 0.5 µL reverse primer (10 µM) and 4 µL 10-fold diluted cDNA. The thermocycler protocol consisted of 10 min at 95 °C and 40 cycles of 10 s at 95 °C and 35 s at 60 °C, and melt curves were added. GAPDH and 18 S were used as housekeeping genes. mRNA relative expression was calculated using the $2^{-\Delta\Delta C_t}$ method.

Western blotting. Total protein was extracted with lysis buffer (KeyGEN, Nanjing, China). Protein supernatant was separated by 10% SDS-PAGE and transferred onto a nitrocellulose membrane. After blocking with 5% skimmed milk powder, the membrane was incubated with the appropriate primary antibodies overnight at 4 °C, followed by incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h. Bands were detected using ECL (ClinX, Shanghai, China). Band intensity was quantified using ImageJ software. Primary antibodies for β -actin (Abcam, MA, USA), MyD88, phosphorylated NF- κ B (Santa Cruz, CA, USA), phosphorylated I κ B- α , phosphorylated AKT (Epitomics, USA), TLR4, zonula occluden-1 (ZO-1), occludin, and claudin-1 (Abcam) were used in this study.

Microbial composition analysis. Genomic DNA was extracted from feces using a Fecal DNA Kit (SimGEN, Hangzhou, China). The DNA was quantified using a NanoDrop 2000 spectrophotometer. Quantitative measurements of total bacteria (forward: CGGTGAATACGTTTCYCGG; reverse: GGWTACCTTGTTCAGACTT), *Escherichia coli* (forward: CATGCCGCGTGTATGAAGAA; reverse: CGGGTAACGTCAATGA GCAAA), and *Lactobacillus* (forward: CGATGAGTGCTAGGTGTTGGA; reverse: CAAGATGTCAAGACCTGGTAAG) were performed by real-time PCR using a StepOne Plus™ System as previously described²⁵.

Gas chromatographic analysis. Concentrations of short-chain fatty acids (SCFAs) in feces were determined via gas chromatography (GC-8 A, Shimadzu Corp., Kyoto, Japan). Briefly, 1 g of feces was mixed with 5 mL ddH₂O and then centrifuged for 15 min at 10,000 × g and 4 °C. Then, 1 mL of supernatant was mixed with 20 µL orthophosphoric acid (85%) for 1 h at 4 °C and centrifuged for 15 min at 12,000 × g and 4 °C. The supernatant was transferred into a gas chromatography vial, and 2 µL of supernatant was injected into a 2-m × 3-mm glass column packed with Porapak Q (80 mesh; Agilent Technologies Inc., Santa Clara, CA, USA) as previously described²⁶. SCFA concentrations were normalized to feces weight as µmol/g.

Cell culture. Cells were cultured in RPMI-1640 or DMEM-F12 medium (Invitrogen) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin sulfate) at 37 °C with 5% CO₂ in a humidified incubator before treatment.

Porcine macrophage cells (3D4/2) were incubated for 6 h either with medium only or with 1 µg/mL lipopolysaccharide (LPS, *Escherichia coli* strain O111:B4, Sigma-Aldrich) after pretreatment with Enro (5, 10, 20, or 40 µg/mL) or CWA (5, 10, 20, or 40 µg/mL) for 12 h. Small-interfering RNA (siRNA) molecules targeting pig TLR4 or MyD88 were designed by Yingrun Biotechnology Co., Ltd. (Changsha, China). The 3D4/2 cells were transfected with 1 µg/mL siRNA using Lipofectamine-2000 (Invitrogen) for 6 h. Then, the transfected cells were incubated with medium only, LPS (1 µg/mL for 6 h), or CWA + LPS (pretreated with 20 µg/mL CWA for 12 h and then 1 µg/mL LPS for 6 h). Culture supernatant was collected for ELISA.

Porcine jejunal epithelial cells (IPEC-J2) were cultured in transwell dishes for at least 21 d until their transepithelial electrical resistance (TER) was stable. Monolayers of IPEC-J2 cells were incubated for 12 h with serum-free medium, LPS (1 µg/mL), or CWA + LPS (pretreated with 20 µg/mL CWA for 12 h and then 1 µg/mL LPS added) in the upper layer. TER was measured using a Millicell ERS-2 epithelial volt-ohm meter (Millipore MERS00002, USA). Cells were collected for Western blotting.




Figure 1. Cathelicidin-WA attenuated diarrhea and reduced serum pro-inflammatory cytokine levels in weaned piglets. (A) The diarrheal index was measured using fecal consistency scoring (0, normal; 1, soft feces; 2, mild diarrhea; and 3, severe diarrhea). (B) A fecal score of either 2 or 3 was considered to represent clinical diarrhea, and the diarrhea ratio was calculated. (C) Average daily gain. Serum levels of the pro-inflammatory cytokines IL-6 (D), IL-8 (E), and IL-22 (F) were determined by ELISA. All data are expressed as the mean \pm SEM (n = 6). Differences were determined by one-way ANOVA. Ero, Enrofloxacin; CWA, Cathelicidin-WA. * $P < 0.05$ compared with control; # $P < 0.05$ CWA compared with Ero.

Caco-2 cells were cultured in 35-mm dishes. Caco-2 monolayers were scraped with 200- μ L pipette tips as previously described²⁷. The scraped Caco-2 cells were incubated with medium only or 20 μ g/mL CWA. Images were obtained at 0 h, 48 h and 96 h. Wound width was measured at 48 h.

Statistical analysis. Statistical analysis was performed using one-way ANOVA or Student's t-test with SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Differences were considered significant at $P < 0.05$.

Result

CWA effectively attenuated diarrhea and systematic inflammation in weaned piglets. Both CWA and Ero effectively decreased the diarrheal index and the diarrheal ratio and increased body weight gain compared with the control (Fig. 1A–C). Furthermore, CWA and Ero showed no significant differences in the diarrheal index, the diarrhea ratio, or body weight gain. Compared with the control, CWA treatment reduced levels of the pro-inflammatory cytokines IL-6, IL-8 and IL-22 in serum, whereas Ero treatment reduced levels of IL-6 and IL-22 (Fig. 1D–F). These data indicate that the CWA may be an effective alternative to antibiotics for the treatment of diarrhea in weaned piglets.

CWA improved intestinal morphology and integrity in weaned piglets. CWA treatment increased villous height in the jejunum compared with control and Ero treatments (Fig. 2A,E); this result was confirmed via SEM at 150 \times magnification (Fig. 2B). In addition, surface damage to villi in the jejunum was alleviated by CWA and Ero treatments (Fig. 2B, upper). Interestingly, both CWA and Ero increased the quantity of microvilli in the jejunum (Fig. 2B,C). Furthermore, CWA increased the height of microvilli in the jejunum compared with control and Ero (Fig. 2C,F). These results suggest that CWA effectively improved intestinal morphology and integrity in weaned piglets with clinical diarrhea.

CWA suppressed intestinal inflammation via TLR4-, MyD88-, and NF- κ B-dependent pathways. Levels of the pro-inflammatory cytokines IL-6, IL-8, and IL-22 in the jejunum were detected by ELISA. Both CWA and Ero significantly inhibited IL-6, IL-8 and IL-22 production in the jejunum compared with the control (Fig. 3A). In addition, immunohistochemistry results demonstrated that both CWA and Ero effectively decreased neutrophil infiltration in the mucosa of the jejunum compared with the control (Fig. 3B). Compared with the control, both CWA and Ero decreased the gene and protein expressions of TLR4 and MyD88 in the jejunum (Fig. 3C). Consequently, phosphorylation of NF- κ B, I κ B- α and AKT was suppressed in the jejunum following treatment with CWA and Ero (Fig. 3D). There were no significant differences between CWA and Ero regarding the suppression of intestinal inflammation *in vivo* in this study. However, *in vitro*, although Ero had no effects on LPS-induced expression of the pro-inflammatory cytokine IL-6 in porcine macrophages, CWA showed excellent inhibition of IL-6 production in a concentration-dependent manner (Fig. 4A). Furthermore, using




Figure 2. Cathelicidin-WA improved intestinal morphology. Jejunum sections were used to analyze intestinal morphology. (A) Stained with H&E (bars, 200 μm). (B) SEM images (upper, 150 \times ; lower, 30,000 \times). (C) TEM images (bars, 0.5 μm). (D) Histological scores were determined as described in the *Materials and Methods*. (E) Villous height in the jejunum. (F) Microvillus height was measured using TEM. All data are expressed as the mean \pm SEM (n = 6). Differences were determined by one-way ANOVA. Enro, Enrofloxacin; CWA, Cathelicidin-WA. * $P < 0.05$ compared with control; # $P < 0.05$ CWA compared with Enro.

siRNA-mediated knockdown, we found that CWA had no significant effects on LPS-induced IL-6 expression in MyD88-silenced or TLR4-silenced macrophages (Fig. 4B). These findings indicate that CWA shows excellent suppression of intestinal inflammation and may be involved in TLR4-, MyD88- and NF- κ B-dependent pathways.




Figure 3. Cathelicidin-WA suppressed jejunal inflammation. (A) Levels of the pro-inflammatory cytokines IL-6, IL-8, and IL-22 in the jejunum. (B) Neutrophil infiltration into the mucosa of the jejunum was determined by immunohistochemical staining with an antibody against MPO (bars, 100 μ m). (C) Relative mRNA expression and protein levels of TLR4 and MyD88 in the jejunum. (D) The phosphorylation of NF- κ B, I κ B- α , and AKT was determined by Western blotting. All data are expressed as the mean \pm SEM (n = 6). Differences were determined by Student's t-test. Enro, Enrofloxacin; CWA, Cathelicidin-WA. * $P < 0.05$ compared with control.

CWA enhanced intestinal barrier functions. Both CWA and Enro decreased serum D-Lac levels compared with the control (Fig. 5A). Furthermore, Enro significantly reduced the expression of mucin-1 (MUC-1), mucin-2 (MUC-2) and porcine beta-defensin-2 (pBD2) mRNA in the jejunum compared with the control and CWA (Fig. 5B). In addition, we performed Western blot analysis to detect the expression of ZO-1, occludin and claudin-1. Although Enro had no significant effects on claudin-1 expression, ZO-1 and occludin expression levels in the jejunum were significantly reduced by Enro compared with the control (Fig. 5C,D). However, CWA significantly increased ZO-1 and occludin expression in the jejunum compared with the control (Fig. 5C,D). To verify these findings, we tested the effects of CWA on epithelial barriers *in vitro*. We found that CWA effectively ameliorated LPS-induced decreases in TER in IPEC-J2 cells (Fig. 5E). Furthermore, the expression levels of ZO-1 and occludin proteins in LPS-induced IPEC-J2 cells were increased by CWA (Fig. 5F). Interestingly, CWA significantly reduced wound width at 48 h in a scrape assay in Caco-2 cells (Fig. 5G,H), suggesting that CWA could be beneficial for healing damage to intestinal epithelial cells. Collectively, CWA enhanced the intestinal barrier by increasing the expression of TJ proteins and augmenting wound healing ability. By contrast, Enro treatment may disrupt the intestinal barrier by decreasing the expression of TJ proteins and antimicrobial proteins.

CWA improved microbial composition and SCFA levels in feces. To evaluate CWA's effects on intestinal epithelial barrier-microbiota interactions, we evaluated microbiota composition and SCFAs in the feces of weaned piglets following CWA treatment. Both CWA and Enro decreased the ratio of *Escherichia coli* to total bacteria and increased the ratio of *Lactobacillus* to *Escherichia coli* in feces compared with the control (Fig. 6A,C).

The ratio of *Lactobacillus* to total bacteria in feces was decreased by Enro but increased by CWA compared with the control (Fig. 6B). Furthermore, CWA increased acetate, propionate and butyrate concentrations, but it did not alter the ratios of propionate/acetate, butyrate/acetate and butyrate/propionate in feces compared with the control (Fig. 6D–J). By contrast, Enro not only decreased butyrate concentration but also reduced the ratios of butyrate/propionate and butyrate/acetate in feces compared with the control and CWA (Fig. 6E,H,J).

Discussion

In this study, we demonstrated that the CWA can effectively attenuate postweaning diarrhea by suppressing inflammation, enhancing barrier function, and improving microbiota composition and SCFA levels in the intestine of piglets. By contrast, the antibiotic Enro disrupted barrier function, changed microbiota composition and negatively impacted SCFA levels in the intestine. Collectively, these data indicate that CWA could be an effective and safe therapy for diarrhea or other intestinal diseases and may have the potential to reduce antibiotic use in young mammals.

Diarrhea is a leading cause of death in young children, especially during the weaning period. Antibiotics are usually used for the treatment of diarrhea. In this study, we selected weaned piglets with clinical diarrhea as models to compare the effects of CWA and the antibiotic Enro on diarrhea in young mammals. To reduce the influence of bacterial resistance, we chose to evaluate Enro in this study, which is currently approved by the FDA and has strong antibacterial activity against both Gram-negative and Gram-positive bacteria. Surprisingly, we found that CWA attenuated diarrhea in weaned piglets as effectively as Enro. This is the first study to demonstrate that AMPs

the TLR4-, MyD88- and NF- κ B-dependent pathways in weaned piglets with diarrhea. Consistent with our results, previous studies have shown that cathelicidin peptides can decrease pro-inflammatory cytokine levels by inhibiting the NF- κ




Figure 6. Cathelicidin-WA improved microbial composition and SCFA levels in feces. Ratios of *Escherichia coli* to total bacteria (A), *Lactobacillus* to total bacteria (B), and *Lactobacillus* to *Escherichia coli* (C) in feces as detected by qPCR. The concentrations of acetate (D), propionate (E), and butyrate (F) in feces were determined by GS, and the data were normalized to feces weight (per gram). Ratios of propionate/acetate (G), butyrate/propionate (H) and butyrate/acetate (J). All data are expressed as the mean \pm SEM (n = 6). Differences were determined by one-way ANOVA. Enro, Enrofloxacin; CWA, Cathelicidin-WA. * $P < 0.05$ compared with the control; # $P < 0.05$ CWA compared with Enro.

As Enro treatment also effectively suppressed intestinal inflammation in weaned piglets, the question arises of whether the anti-inflammatory capacity of CWA is only dependent on its antibacterial activity (such as with antibiotics). Thus, we evaluated the immunomodulatory properties of CWA and Enro in LPS-stimulated porcine macrophages *in vitro*. Interestingly, Enro had no effects on the LPS-induced expression of the pro-inflammatory cytokine IL-6, whereas CWA effectively suppressed IL-6 expression. The differential regulation of IL-6 expression by Enro and CWA in macrophages may be related to the antibiotic-independent immunomodulatory effects of cathelicidins. Cathelicidins have been reported to suppress LPS-induced inflammation in macrophages via several mechanisms: binding to LPS; perturbation of the MyD88 signaling pathway; and inhibition of NF- κ B translocation^{35,36}. In this study, CWA was used to treat macrophages for 12 h and then removed before LPS treatment; thus, any anti-inflammatory activities of CWA were independent of LPS binding activity in macrophages. In addition to inactivating LPS through binding, a lactoferrin peptide was also shown to modulate LPS-induced inflammatory responses by directly affecting the MyD88-NF- κ B signaling pathway in macrophages³⁷. Consistent with these results, we found that CWA-mediated suppression of IL-6 expression was a direct result of CWA's effects on the TLR4 and MyD88 signaling pathways. Collectively, these data suggest that the mechanisms by which CWA

inhibits inflammation could be mediated by the down-regulation of the TLR4-, MyD88- and NF- κ B-dependent pathways independently of CWA's antibacterial activity. This effect may explain why CWA (0.6 mg/kg) and Enro (2.5 mg/kg) exhibited similar effects on the suppression of intestinal inflammation in weaned piglets with diarrhea.

Intestinal barrier damage is present in many intestinal diseases, such as diarrhea and inflammatory bowel disease (IBD). The epithelial barrier of the intestine is responsible for restricting the invasion of harmful substances, including microbes, toxins and LPS³⁸. TJs are the most apical intercellular structures in the mucosa of the

14. Pasupuleti, M., Schmidtchen, A. & Malmsten, M. Antimicrobial peptides: key components of the innate immune system. *Crit Rev Biotechnol* **32**, 143–171, doi: 10.3109/07388551.2011.594423 (2012).
15. Brogden, K. A., Ackermann, M., McCray, P. B. & Tack, B. F. Antimicrobial peptides in animals and their role in host defences. *International Journal of Antimicrobial Agents* **22**, 465–478 (2003).
16. Giuliani, A., Pirri, G. & Nicoletto, S. F. Antimicrobial peptides: an overview of a promising class of therapeutics. *Central European Journal of Biology* **2**, 1–33, doi: 10.2478/s11535-007-0010-5 (2007).
17. Zhang, H. W. *et al.* Cathelicidin-BF, a Novel Antimicrobial Peptide from *Bungarus fasciatus*, Attenuates Disease in a Dextran Sulfate Sodium Model of Colitis. *Mol Pharmaceut* **12**, 1648–1661 (2015).
18. Tai, E. K. K. *et al.* Intrarectal administration of mCRAMP-encoding plasmid reverses exacerbated colitis in Cnlp(–/–)Imice. *Gene Ther* **20**, 187–193 (2013).
19. Wang, Y. *et al.* Snake cathelicidin from *Bungarus fasciatus* is a potent peptide antibiotics. *PLoS one* **3**, e3217, doi: 10.1371/journal.pone.0003217 (2008).
20. Wang, Y. P. *et al.* Cathelicidin-BF, a Snake Cathelicidin-Derived Antimicrobial Peptide, Could Be an Excellent Therapeutic Agent for Acne Vulgaris. *Plos One* **6** (2011).
21. Wang, J. *et al.* BF-30 effectively inhibits ciprofloxacin-resistant bacteria *in vitro* and in a rat model of vaginosis. *Arch Pharm Res* **37**, 927–936, doi: 10.1007/s12272-013-0248-6 (2014).
22. Liu, Y., Luan, C., Xia, X., An, S. & Wang, Y. Antibacterial Activity, Cytotoxicity and Mechanisms of action of Cathelicidin Peptides against Enteric Pathogens in Weaning Piglets. *International Journal of Peptide Research and Therapeutics* **17**, 175–184, doi: 10.1007/s10989-011-9255-y (2011).
23. Song, D. G. *et al.* Antimicrobial peptide Cathelicidin-BF prevents intestinal barrier dysfunction in a mouse model of endotoxemia. *Int Immunopharmacol* **25**, 141–147 (2015).
24. Bhandari, S. K., Xu, B., Nyachoti, C. M., Giesting, D. W. & Krause, D. O. Evaluation of alternatives to antibiotics using an *Escherichia coli* K88(+) model of piglet diarrhea: Effects on gut microbial ecology. *Journal of animal science* **86**, 836–847, doi: 10.2527/jas.2006-822 (2008).
25. Gao, Y. *et al.* Changes in gut microbial populations, intestinal morphology, expression of tight junction proteins, and cytokine production between two pig breeds after challenge with *Escherichia coli* K88: A comparative study. *J Anim Sci* **91**, 5614–5625, doi: 10.2527/jas.2013-6528 (2013).
26. Wang, B. *et al.* Effects of alfalfa and cereal straw as a forage source on nutrient digestibility and lactation performance in lactating dairy cows. *J Dairy Sci* **97**, 7706–7715 (2014).
27. Pie, S. *et al.* Weaning is associated with an upregulation of expression of inflammatory cytokines in the intestine of piglets. *Journal of Nutrition* **134**, 641–647 (2004).
28. Yi, H. B. *et al.* Cathelicidin-BF suppresses intestinal inflammation by inhibiting the nuclear factor- κ B signaling pathway and enhancing the phagocytosis of immune cells via STAT-1 in weanling piglets. *Int Immunopharmacol* **28**, 61–69 (2015).
29. Nijnik, A. & Hancock, R. E. W. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. *Current Opinion in Hematology* **16**, 41–47, doi: 10.1097/MOH.0b013e32831ac517 (2009).
30. Brown, K. L. *et al.* Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. *J Immunol* **186**, 5497–5505, doi: 10.4049/jimmunol.1002508 (2011).
31. Scott, A. *et al.* Evaluation of the ability of LL-37 to neutralise LPS *in vitro* and *ex vivo*. *PLoS one* **6**, e26525, doi: 10.1371/journal.pone.0026525 (2011).
32. van der Does, A. M., Bergman, P., Agerberth, B. & Lindbom, L. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. *Journal of leukocyte biology* **92**, 735–742, doi: 10.1189/jlb.0412178 (2012).
33. Hilchie, A. L., Wuerth, K. & Hancock, R. E. W. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. *Nat Chem Biol* **9**, 761–768, doi: 10.1038/Nchembio.1393 (2013).
34. Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D. & Hancock, R. E. W. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *Journal of Immunology* **169**, 3883–3891 (2002).
35. Sun, J. *et al.* Pancreatic beta-Cells Limit Autoimmune Diabetes via an Immunoregulatory Antimicrobial Peptide Expressed under the Influence of the Gut Microbiota. *Immunity* **43**, 304–317, doi: 10.1016/j.immuni.2015.07.013 (2015).
36. Bucki, R., Leszczynska, K., Namiot, A. & Sokolowski, W. Cathelicidin LL-37: a multitask antimicrobial peptide. *Archivum immunologiae et therapiae experimentalis* **58**, 15–25, doi: 10.1007/s00005-009-0057-2 (2010).
37. Zong, X. *et al.* LFP-20, a porcine lactoferrin peptide, ameliorates LPS-induced inflammation via the MyD88/NF- κ B and MyD88/MAPK signaling pathways. *Developmental and comparative immunology* **52**, 123–131 (2015).
38. Farhadi, A., Banan, A., Fields, J. & Keshavarzian, A. Intestinal barrier: An interface between health and disease. *J Gastroen Hepatol* **18**, 479–497 (2003).
39. Han, F. F. *et al.* Porcine beta-Defensin 2 Attenuates Inflammation and Mucosal Lesions in Dextran Sodium Sulfate-Induced Colitis. *Journal of Immunology* **194**, 1882–1893 (2015).
40. Mennigen, R. *et al.* Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. *American Journal of Physiology-Gastrointestinal and Liver Physiology* **296**, G1140–G1149 (2009).
41. Gallo, R. L. & Hooper, L. V. Epithelial antimicrobial defence of the skin and intestine. *Nature reviews. Immunology* **12**, 503–516, doi: 10.1038/nri3228 (2012).
42. Brandl, K. *et al.* Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. *Nature* **455**, 804–U808 (2008).
43. Wlodarska, M. & Finlay, B. B. Host immune response to antibiotic perturbation of the microbiota. *Mucosal immunology* **3**, 100–103 (2010).
44. Wu, S. D. *et al.* Effects of the antimicrobial peptide cecropin AD on performance and intestinal health in weaned piglets challenged with *Escherichia coli*. *Peptides* **35**, 225–230, doi: 10.1016/j.peptides.2012.03.030 (2012).
45. Xiao, H. *et al.* Effects of composite antimicrobial peptides in weanling piglets challenged with deoxynivalenol: I. Growth performance, immune function, and antioxidation capacity. *J Anim Sci* **91**, 4772–4780 (2013).
46. Yoon, J. H. *et al.* Effects of dietary supplementation of synthetic antimicrobial peptide-A3 and P5 on growth performance, apparent total tract digestibility of nutrients, fecal and intestinal microflora and intestinal morphology in weanling pigs. *Livest Sci* **159**, 53–60, doi: 10.1016/j.livsci.2013.10.025 (2014).
47. Sekirov, I. *et al.* Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. *Infection and immunity* **76**, 4726–4736 (2008).

Acknowledgements

This study was funded by the National Science Fund for Distinguished Young Scholars of China (Grant No. 31025027), the National Natural Science Foundation of China (Grant No. 31572411) and the Modern Agro-Industry Technology Research System of China (CARS-36).

Author Contributions

H.Y. and H.X. fed the piglets and performed the qPCR and Western blot experiments. C.Y. performed the ELISA experiments. L.Z. supervised the TEM and SEM experiments. Z.G. and performed the IPEC-J2 and Caco-2 experiments. Y.W., H.D. and H.Y. directed the research and wrote the manuscript. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yi, H. *et al.* High therapeutic efficacy of Cathelicidin-WA against postweaning diarrhea via inhibiting inflammation and enhancing epithelial barrier in the intestine. *Sci. Rep.* **6**, 25679; doi: 10.1038/srep25679 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>